Anticipated acquisition by AstraZeneca UK Limited of Cambridge Antibody Technology plc
Affected market: BiopharmaceuticalsNo. ME/2433/06
On the basis of the information available to it, the OFT has decided that the anticipated acquisition by AstraZeneca UK Limited of Cambridge Antibody Technology plc does not qualify for investigation under the mergers provisions of the Enterprise Act 2002 (the Act), because neither the UK turnover test nor the share of supply test in section 23 of the Act is met. A relevant merger situation has, therefore, not been created.
- OFT telephone enquiries:08457 22 44 99
- Consumer Direct telephone enquiries:08454 04 05 06